Diabetic Peripheral Neuropathy - Pipeline Review, H1 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Diabetic Peripheral Neuropathy - Pipeline Review, H1 2017" report to their offering.

This report provides comprehensive information on the therapeutic development for Diabetic Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Peripheral Neuropathy and special features on late-stage and discontinued projects.

Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legs and feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain or discomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tone in the feet and lower legs, loss of balance, dry feet and cracked skin. The predisposing factors include diabetes, smoking and kidney diseases. Treatment includes antidepressants, anti-seizure and opioid analgesics.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Diabetic Peripheral Neuropathy Overview
  3. Therapeutics Development
  4. Pipeline Products for Diabetic Peripheral Neuropathy - Overview
  5. Pipeline Products for Diabetic Peripheral Neuropathy - Comparative Analysis
  6. Diabetic Peripheral Neuropathy - Therapeutics under Development by Companies
  7. Diabetic Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes
  8. Diabetic Peripheral Neuropathy Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Diabetic Peripheral Neuropathy - Products under Development by Companies
  13. Diabetic Peripheral Neuropathy - Products under Investigation by Universities/Institutes
  14. Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development
  • Achelios Therapeutics Inc
  • Celgene Corp
  • Commence Bio Inc
  • KPI Therapeutics Inc
  • Medifron DBT Co Ltd
  • Relief Therapeutics Holding AG
  • ViroMed Co Ltd

For more information about this report visit http://www.researchandmarkets.com/research/vrnzcz/diabetic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs , Endocrine and Metabolic Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs , Endocrine and Metabolic Disorders Drugs